An Improved Animal Model of Multiple Myeloma Bone Disease
| Autor: | Syed Hassan Mehdi, Donghoon Yoon, Carol A Morris, Jung Ae Lee |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Bone disease business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Plasma cell medicine.disease Bone resorption Article murine model multiple myeloma bone disease medicine.anatomical_structure Oncology medicine NSG mouse Femur Tibia Bone marrow business severe osteolytic lesions Multiple myeloma RC254-282 |
| Zdroj: | Cancers Volume 13 Issue 17 Cancers, Vol 13, Iss 4277, p 4277 (2021) |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13174277 |
| Popis: | Simple Summary Multiple myeloma is a plasma cell cancer involving bone destruction and is considered an incurable disease despite significant improvements in therapeutic strategies. During myeloma progression, over 90% of patients develop a bone disease that causes patient injury and death. There are limited animal models available to demonstrate multiple myeloma bone disease (MMBD). The current study identifies and validates the newly developed MMBD models with uniformity of tumor burden and severe bone lesions. This model will help study the biology of MMBD and serve as a valuable tool for screening therapeutic candidates by monitoring their response to disease progression. Abstract Multiple myeloma (MM) is a plasma cell malignancy that causes an accumulation of terminally differentiated monoclonal plasma cells in the bone marrow, accompanied by multiple myeloma bone disease (MMBD). MM animal models have been developed and enable to interrogate the mechanism of MM tumorigenesis. However, these models demonstrate little or no evidence of MMBD. We try to establish the MMBD model with severe bone lesions and easily accessible MM progression. 1 × 106 luciferase-expressing 5TGM1 cells were injected into 8–12 week-old NOD SCID gamma mouse (NSG) and C57BL/KaLwRij mouse via the tail vein. Myeloma progression was assessed weekly via in vivo bioluminescence (BL) imaging using IVIS-200. The spine and femur/tibia were extracted and scanned by the micro-computer tomography for bone histo-morphometric analyses at the postmortem. The median survivals were 56 days in NSG while 44.5 days in C57BL/KaLwRij agreed with the BL imaging results. Histomorphic and DEXA analyses demonstrated that NSG mice have severe bone resorption that occurred at the lumbar spine but no significance at the femur compared to C57BL/KaLwRij mice. Based on these, we conclude that the systemic 5TGM1 injected NSG mouse slowly progresses myeloma and develops more severe MMBD than the C57BL/KaLwRij model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|